Clinical Trial Update: Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates [Phase 1, Phase 2]

View source ↗

Summary

A neoadjuvant trial evaluating paclitaxel alone versus BIBF 1120 priming followed by BIBF 1120 plus paclitaxel in early HER-2 negative breast cancer with proteo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BIBF 1120 (nintedanib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED